188 related articles for article (PubMed ID: 16804637)
1. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease.
Hamaguchi T; Ono K; Yamada M
Cell Mol Life Sci; 2006 Jul; 63(13):1538-52. PubMed ID: 16804637
[TBL] [Abstract][Full Text] [Related]
2. The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta.
Ono K; Naiki H; Yamada M
Curr Pharm Des; 2006; 12(33):4357-75. PubMed ID: 17105432
[TBL] [Abstract][Full Text] [Related]
3. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
Conway KA; Baxter EW; Felsenstein KM; Reitz AB
Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
6. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
7. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
Cho JE; Kim JR
Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
[TBL] [Abstract][Full Text] [Related]
8. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
9. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
10. Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.
Lakey-Beitia J; Berrocal R; Rao KS; Durant AA
Mol Neurobiol; 2015 Apr; 51(2):466-79. PubMed ID: 24826916
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches to Alzheimer's disease through stimulating of non-amyloidogenic processing of amyloid precursor protein.
Wang YQ; Qu DH; Wang K
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2389-403. PubMed ID: 27338066
[TBL] [Abstract][Full Text] [Related]
13. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
14. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Amyloid Hypothesis in Alzheimer's Disease.
Paroni G; Bisceglia P; Seripa D
J Alzheimers Dis; 2019; 68(2):493-510. PubMed ID: 30883346
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action.
Sharma S; Nehru B; Saini A
Neurochem Int; 2017 Sep; 108():481-493. PubMed ID: 28652220
[TBL] [Abstract][Full Text] [Related]
17. GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.
Tian J; Shi J; Zhang L; Yin J; Hu Q; Xu Y; Sheng S; Wang P; Ren Y; Wang R; Wang Y
Curr Alzheimer Res; 2009 Apr; 6(2):118-31. PubMed ID: 19355846
[TBL] [Abstract][Full Text] [Related]
18. Effect of trichostatin A on gelsolin levels, proteolysis of amyloid precursor protein, and amyloid beta-protein load in the brain of transgenic mouse model of Alzheimer's disease.
Yang W; Chauhan A; Wegiel J; Kuchna I; Gu F; Chauhan V
Curr Alzheimer Res; 2014; 11(10):1002-11. PubMed ID: 25387339
[TBL] [Abstract][Full Text] [Related]
19. Unveiling the Potential of Polyphenols as Anti-Amyloid Molecules in Alzheimer's Disease.
Kabir ER; Chowdhury NM; Yasmin H; Kabir MT; Akter R; Perveen A; Ashraf GM; Akter S; Rahman MH; Sweilam SH
Curr Neuropharmacol; 2023; 21(4):787-807. PubMed ID: 36221865
[TBL] [Abstract][Full Text] [Related]
20. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.
Meilandt WJ; Cisse M; Ho K; Wu T; Esposito LA; Scearce-Levie K; Cheng IH; Yu GQ; Mucke L
J Neurosci; 2009 Feb; 29(7):1977-86. PubMed ID: 19228952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
